Cited by 261Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentPsychedelics and Drug Studies

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

A systematic review of the antipsychotic properties of cannabidiol in humans

Open access

Iseger, Tabitha A., Bossong, Matthijs G.·2015·Schizophrenia Research

DOI 10.1016/j.schres.2015.01.033

Open this paper in CoChat — free account

Abstract

Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces acute psychotic effects and cognitive impairment. However, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (CBD) may have antipsychotic properties, and thus may be a promising new agent in the treatment of schizophrenia. Here we review studies that investigated the antipsychotic properties of CBD in human subjects. Results show the ability of CBD to counteract psychotic symptoms and cognitive impairment associated with cannabis use as well as with acute THC administration. In addition, CBD may lower the risk for developing psychosis that is related to cannabis use. These effects are possibly mediated by opposite effects of CBD and THC on brain activity patterns in key regions implicated in the pathophysiology of schizophrenia, such as the striatum, hippocampus and prefrontal cortex. The first small-scale clinical studies with CBD treatment of patients with psychotic symptoms further confirm the potential of CBD as an effective, safe and well-tolerated antipsychotic compound, although large randomised clinical trials will be needed before this novel therapy can be introduced into clinical practice.

Integrity signals

Registry

Crossref · 10.1016/j.schres.2015.01.033

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
Schizophrenia
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,101
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Causal association between cannabis and psychosis: examination of the evidence
Arseneault, L., Cannon, M. D., Witton, J., & Murray, R. M. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.2.110 · Cited by 924
Mismatch negativity in schizophrenia: a meta-analysis
Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.002 · Cited by 742
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders
LINSZEN, D. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040017002 · Cited by 665
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716
Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., & Frank, R. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.4.322 · Cited by 497
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., & Piomelli, D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300558 · Cited by 481
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Englund, A., Morrison, P. D., Nottage, J. F., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 479
Schizophrenia, just the facts
Wyatt, R. J., Alexander, R., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 478
Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users
Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt181 · Cited by 470
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Elevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00008 · Cited by 431
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 430
Being stoned: a review of self‐reported cannabis effects
Green, B., Kavanagh, D. J., & Young, R. M. (2003) · Drug and Alcohol Review · doi:10.1080/09595230310001613976 · Cited by 390
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use
Dean, B., Sundram, S., Bradbury, R., Scarr, E., & Copolov, D. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00552-2 · Cited by 381
Cannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355
Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia
Bossong, M. G., & Niesink, R. J. M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.010 · Cited by 333
Self-citation
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305
Intervention in Individuals at Ultra-High Risk for Psychosis
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G. E., Riecher‐Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze‐Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic–pituitary–adrenal axis
Hill, M. N., McLaughlin, R. J., Morrish, A. C., Viau, V., Floresco, S. B., Hillard, C. J., & Gorzalka, B. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.114 · Cited by 304
Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Morgan, C. J. A., & Curran, H. V. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046649 · Cited by 300
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia
Zavitsanou, K., Garrick, T. M., & Huang, X. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.005 · Cited by 270
Cannabis Use and Age at Onset of Schizophrenia
Veen, N. D., Selten, J., van der Tweel, I., Feller, W., Hoek, H. W., & Kahn, R. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.501 · Cited by 266
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264
Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol
Bhattacharyya, S., Fusar‐Poli, P., Borgwardt, S., Martín‐Santos, R., Nosarti, C., O’Carroll, C., Allen, P., Seal, M. L., Fletcher, P. C., Crippa, J. A. S., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.17 · Cited by 246
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Schubart, C. D., Sommer, I. E., van Gastel, W. A., Goetgebuer, R., Kahn, R. S., & Boks, M. P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.017 · Cited by 238
Potency of Δ9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology*
Potter, D. J., Clark, P., & Brown, M. B. (2008) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2007.00603.x · Cited by 230
Cannabis Use and the Course of Schizophrenia: 10-Year Follow-Up After First Hospitalization
Foti, D., Kotov, R., Guey, L. T., & Bromet, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09020189 · Cited by 224
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222
P300 in Clinical Applications: Meaning, Method, and Measurement
Polich, J. M. (1991) · American Journal of EEG Technology · doi:10.1080/00029238.1991.11080373 · Cited by 216
Cannabis use and misuse prevalence among people with psychosis
Green, B., Young, R. M., & Kavanagh, D. J. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.4.306 · Cited by 216
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
Excessive Brain Volume Loss Over Time in Cannabis-Using First-Episode Schizophrenia Patients
Rais, M., Cahn, W., van Haren, N. E. M., Schnack, H. G., Caspers, E., Pol, H. E. H., & Kahn, R. S. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07071110 · Cited by 207
Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats
Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2342-0 · Cited by 206
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
Wong, D. F., Kuwabara, H., Horti, A. G., Raymont, V., Brašić, J. R., Guevara, M. C., Ye, W., Dannals, R. F., Ravert, H. T., Nandi, A., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.034 · Cited by 204
Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing
Bhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203
Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia?
Solowij, N., & Michie, P. T. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0705 · Cited by 202
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition
Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.011 · Cited by 195
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being
Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001322 · Cited by 195
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia
Newell, K. A., Deng, C., & Huang, X. (2006) · Experimental Brain Research · doi:10.1007/s00221-006-0503-x · Cited by 179
Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops
Buisman‐Pijlman, F. T. A., Rigter, S., Hoek, J. A., Goldschmidt, H., & Niesink, R. J. M. (2005) · Addiction Biology · doi:10.1080/13556210500123217 · Cited by 168
Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol
Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., Mann, K., & Hermann, D. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.020 · Cited by 162
Excessive Brain Volume Loss Over Time in Cannabis-Using First-Episode Schizophrenia Patients
Buckley, P. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79181-3 · Cited by 159
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 150
Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study
Winton-Brown, T. T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Martin-Santos, R., Ffytche, D., Zuardi, A. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.17 · Cited by 146 · cited 3×
“…Wernicke's area, during auditory processing and in the right occipital cortex during visual processing, both in comparison to placebo aswell as to THC. Activity after CBDwas reduced in the left superior temporal gyrus during auditory processing when compared to placebo (Winton-Brown et al., 2011).”
BackgroundInfluential
Dorsolateral Prefrontal Cortex N-Acetylaspartate/Total Creatine (NAA/tCr) Loss in Male Recreational Cannabis Users
Hermann, D., Sartorius, A., Welzel, H., Walter, S., Skopp, G., Ende, G., & Mann, K. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.027 · Cited by 135
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Hallak, J. E. C., Machado‐de‐Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C. M. F., Chaves, C., Bernardo, S. A., Regalo, S. C. H., & Zuardi, A. W. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000100011 · Cited by 129
Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Dalton, W. S., Martz, R. C., Lemberger, L., Rodda, B. E., & Forney, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976193300 · Cited by 123
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
Ceccarini, J., Binder, M. D., van Winkel, R., Peuskens, J., Bormans, G. M., Kranaster, L., Enning, F., Koethe, D., Leweke, F. M., & Laere, K. V. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.052 · Cited by 108
Cannabidiol as a potential treatment for psychosis
Schubart, C. D., Sommer, I. E., Fusar‐Poli, P., de Witte, L. D., Kahn, R. S., & Boks, M. P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.002 · Cited by 105
Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex
Dalton, V. S., Long, L. E., Weickert, C. S., & Zavitsanou, K. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.43 · Cited by 104
Effects of acute oral Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers
Roser, P., Juckel, G., Rentzsch, J., Nadulski, T., Gallinat, J., & Stadelmann, A. M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.008 · Cited by 88
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83
Default Mode Network in the Effects of Δ9-Tetrahydrocannabinol (THC) on Human Executive Function
Bossong, M. G., Jansma, J. M., van Hell, H. H., Jager, G., Kahn, R. S., & Ramsey, N. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070074 · Cited by 75
Self-citation
Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies
Bossong, M. G., Jager, G., Bhattacharyya, S., & Allen, P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990436 · Cited by 75
Self-citation
Cannabinoid-induced alterations in brain disposition of drugs of abuse 11Abbreviations: THC, tetrahydrocannabinol; CBD, cannabidiol; PCP, phencyclidine; MDMA, 3,4-methylenedioxyphenyl-methamphetamine HCl.
Reid, M. J. A., & Bornheim, L. M. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00616-5 · Cited by 70
Acute effects of Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity
Juckel, G., Roser, P., Nadulski, T., Stadelmann, A. M., & Gallinat, J. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.015 · Cited by 64
Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC)
Bossong, M. G., Jansma, J. M., Bhattacharyya, S., & Ramsey, N. F. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.017 · Cited by 62
Self-citation
Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
Roser, P., Gallinat, J., Weinberg, G., Juckel, G., Gorynia, I., & Stadelmann, A. M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0868-5 · Cited by 60
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia
Jenko, K. J., Hirvonen, J., Henter, I. D., Anderson, K. B., Zoghbi, S. S., Hyde, T. M., Deep‐Soboslay, A., Innis, R. B., & Kleinman, J. E. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.021 · Cited by 48
Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential
Stadelmann, A. M., Juckel, G., Arning, L., Gallinat, J., Epplen, J. T., & Roser, P. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.04.003 · Cited by 35
Fine motor performance before and after treatment in schizophrenic and schizoaffective patients
Goode, D. J., Manning, A. A., Middleton, J. F., & Williams, B. (1981) · Psychiatry Research · doi:10.1016/0165-1781(81)90071-8 · Cited by 18

Research works printed but not linked: 1

Zuardi, 1984, Pharmacological interaction between 9-tetrahydrocannabinol and cannabidiol, two active constituents of Cannabis sativa, Ciênc. Cult., 36, 386

Sorted by citations

Cannabis sativa: The Plant of the Thousand and One Molecules
Andre, C. M., Hausman, J.-F., & Guerriero, G. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00019 · Cited by 1,544
“The protective role that CBD could play to alleviate these negative effects is now well established and documented (Iseger and Bossong, 2015).”
Background
An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Foll, B. L., Hall, W., Rehm, J. T., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 474

See all 261

Authors: Iseger, T. A., & Bossong, M. G.
Affiliations: King's College London (GB)
Corresponding author: Bossong, Matthijs G.
ORCID: Iseger, Tabitha A.
Bossong, Matthijs G.
Venue: Schizophrenia Research
Publisher: Elsevier BV
Published: 2015-03
Volume: 162
Issue: 1-3
Pages: 153-161
ISSN: 0920-9964 (ISSN-L)
DOI: 10.1016/j.schres.2015.01.033
OpenAlex: W2135363891
Cited by: 261
References: 81
Citations by year: 2026: 3 · 2025: 18 · 2024: 16 · 2023: 15 · 2022: 19 · 2021: 30 · 2020: 32 · 2019: 27 · 2018: 36 · 2017: 29 · 2016: 22 · 2015: 13
FWCI: 4.18
Type: journal article
Language: en
Open access: green
dspace.library.uu.nl
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Schizophrenia Research (publishedVersion)
PubMed (publishedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Research Portal (King's College London) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords: cannabidiol
MeSH terms: Brain, Cannabidiol, Humans, Psychotic Disorders, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A systematic review of the antipsychotic properties of cannabidiol in humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks